Nanoparticle-Based Dressing: The Future of Wound Treatment?

Asadi

J of Applied Polymer Sci

2018

Bioactive wound dressings from poly(vinyl alcohol) (PVA) and zein nanoparticles (NPs) loaded with diclofenac (DLF) were prepared successfully by the single jet electrospinning method. DLF‐loaded zein NPs with an average diameter of ∼228 nm were prepared using anti‐solvent precipitation method. The formulation of zein:DLF 1:1 exhibited optimum encapsulation efficiency of 47.80%. The NPs were characterized by dynamic light scattering, zeta‐potential measurement, and differential scanning calorimetry. In vitro, drug release profiles of the DLF‐loaded zein NPs, and PVA–zein NPs were also studied within 120 h and showed the release efficiency of nearly 80% from zein NPs. A more controlled release of DLF was achieved by embedding the zein NPs in the PVA nanofibers. Fourier transform infrared spectroscopy was used to analyze possible interactions between different components of the fabricated dressings. The mechanical properties of the developed dressings were also evaluated using uniaxial tensile testing. Young's modulus (E) of the dressings decreased after inclusion of zein NPs within the PVA nanofibers. Moreover, fibroblast culturing experiments proved that the composite dressings supported better cell attachment and proliferation compared to PVA nanofibers, by exhibiting moderate hydrophilicity. The results suggested that the electrospun composite dressing of PVA nanofibers and zein NPs is a promising topical drug‐delivery system and have a great potential for wound healing application. © 2018 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2018, 135, 46643.

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Zein nanoparticle‐embedded electrospun PVA nanofibers as wound dressing for topical delivery of anti‐inflammatory diclofenac

Asadi

J of Applied Polymer Sci

2018

Adv Healthcare Materials

“…Wound healing follows a dynamic and orderly process, and according to the nature of wound healing, it can be classified into acute wound and chronic wound . Acute wounds, also known as normal wounds, are usually caused by mechanical, burn, or chemical injuries .…”

Section: Causes and Healing Of Woundsmentioning

confidence: 99%

“…into acute wound and chronic wound. [20][21][22][23] Acute wounds, also known as normal wounds, are usually caused by mechanical, burn, or chemical injuries. [24][25][26] The wounds can be completely healed with the smallest scar, and the healing time is usually 8-12 weeks.…”

Section: Introductionmentioning

confidence: 99%

Advances and Impact of Antioxidant Hydrogel in Chronic Wound Healing

Han

et al. 2020

451

305

The accelerating and thorough treatment of chronic wounds still represents a major unmet medical need owing to the complex symptoms resulting from metabolic disorder of the wound microenvironment. Although numerous strategies and bioactive hydrogels are developed, an effective and widely used method of chronic wound treatment remains a bottleneck. With the aim to accelerate chronic wound healing, many hydrogel dressings with antioxidant functions have emerged and are proven to accelerate wound healing, especially for chronic wound repair. The new strategy in chronic wound treatment brought by antioxidant hydrogels is of great significance to human health. Here, the application of antioxidant hydrogels in the repair of chronic wounds is discussed systematically, aiming to provide an important theoretical reference for the further breakthrough of chronic wound healing.

“…Topical administration of drug-loaded NPs allows optimal delivery to the dermis and improves product efficacy. Scaffold-associated NPs reflect also a new concept of 'dressing' that has shown benefits in preclinical models [25].…”

Section: Skin Reconstitutionmentioning

confidence: 99%

An Industry update: the Latest Developments in Therapeutic Delivery

Steinbach

2017

Ther. Deliv.

The present industry update covers the period 1-30 June 2017, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. The combination of drug and devices such as improved, safer injectables (see various market reports, companies Adamis and Baxter), patches (Microdermis) and (nano)carriers are moving increasingly from the R&D stage into clinical trials and toward the market. This addresses increased safety and effectiveness requirements, limiting physicochemical properties of active ingredients, cost-effectiveness and patient comfort through ease of use. Further attention in the market is on local delivery methods (such as intraocular by Icon Bioscience, Glaukos) and the sheer infinite possibilities of nanotechnology such as LDL nanocarriers, microneedles and hydrogel cubes. Another 21st century key technology area is mobile applications (Vital Art and Science) and connected devices (SmartPill, Pop Test Devices) which are increasingly finding their way into the drug delivery field to enable, for example, closed loop monitoring of drug dosing in trials and of patients with their care providers. Not surprisingly companies are increasingly utilizing convergence to combine their diverse capabilities (Vetter Pharma/Microdermis, TXCell/Lentigen Technology).